Journal Article DKFZ-2025-02896

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
TROPHIT1—a randomized, open-label, multicenter, phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic colorectal cancer patients

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2025
Elsevier B.V. [Amsterdam]

ESMO gastrointestinal oncology 7, 100118 () [10.1016/j.esmogo.2024.100118]
 GO

Classification:

Note: DKFZ-ZMBH Alliance / #EA:D120#LA:A013#

Contributing Institute(s):
  1. DKTK HD zentral (HD01)
  2. Angewandte Tumor-Immunität (D120)
  3. Krebsepidemiologie (C180)
  4. Bewegung, Krebsprävention und Survivorship (C110)
  5. Translationale Medizinische Onkologie (B340)
  6. A010 Stammzellen und Krebs (A010)
  7. NWG Tumorprogression und Metastasierung (A013)
Research Program(s):
  1. 311 - Zellbiologie und Tumorbiologie (POF4-311) (POF4-311)

Appears in the scientific report 2025
Database coverage:
DOAJ ; Article Processing Charges ; DOAJ Seal ; Fees
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Institute Collections > D120
Public records
Publications database

 Record created 2025-12-11, last modified 2025-12-30



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)